Empire Resorts, Inc. (NYNY) Trades at $21.25 After Triangle; Newlink Genetics (NLNK) Sentiment Is 1.18

NewLink Genetics Corporation (NASDAQ:NLNK) Logo

Newlink Genetics Corp (NLNK) investors sentiment decreased to 1.18 in Q1 2018. It’s down -0.33, from 1.51 in 2017Q4. The ratio fall, as 53 investment professionals started new or increased stock positions, while 45 sold and reduced holdings in Newlink Genetics Corp. The investment professionals in our database reported: 18.74 million shares, down from 23.56 million shares in 2017Q4. Also, the number of investment professionals holding Newlink Genetics Corp in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 18 Reduced: 27 Increased: 35 New Position: 18.

Empire Resorts, Inc. (NYNY) formed triangle with $20.19 target or 5.00% below today’s $21.25 share price. Empire Resorts, Inc. (NYNY) has $695.63M valuation. The stock increased 0.71% or $0.15 during the last trading session, reaching $21.25. About 109 shares traded. Empire Resorts, Inc. (NASDAQ:NYNY) has declined 16.57% since June 12, 2017 and is downtrending. It has underperformed by 29.14% the S&P500. Some Historical NYNY News: ; 22/04/2018 – DJ Empire Resorts Inc, Inst Holders, 1Q 2018 (NYNY); 27/03/2018 Empire Resorts, Inc. Participates in Problem Gambling Awareness Month; 27/03/2018 – Empire Resorts Declines Most in More Than Two Years; 15/05/2018 – Empire Resorts Sees Opportunity in Supreme Court Decision on Sports Betting; 09/04/2018 – Empire Resorts Advances Most in More Than Two Years

The stock increased 0.58% or $0.03 during the last trading session, reaching $5.19. About 1,955 shares traded. NewLink Genetics Corporation (NLNK) has declined 64.57% since June 12, 2017 and is downtrending. It has underperformed by 77.14% the S&P500. Some Historical NLNK News: ; 06/04/2018 – NEWLINK TO REVIEW CLINICAL PROGRAMS AFTER INCYTE’S ANNOUNCEMENT; 06/04/2018 – The fallout over $INCY setback continues at $BMY and $NLNK, adding a note about NewLink program review in light of PhIII failure; 18/05/2018 – U.S. FDA – ISSUES ALERT ABOUT DECREASED SURVIVAL ASSOCIATED WITH THE USE OF KEYTRUDA (PEMBROLIZUMAB) OR TECENTRIQ (ATEZOLIZUMAB); 21/03/2018 – NewLink Genetics Appoints Chad a. Johnson to Bd of Directors; 01/05/2018 – NewLink Genetics Appoints Matthew L. Sherman, M.D. to Board of Directors; 10/05/2018 – Exelixis Says Combination of Atezolizumab and Cobimetinib Didn’t Deliver an Improvement in Overall Survival Versus Regorafenib; 07/05/2018 – FDA Grants Priority Review to Genentech’s Cancer Immunotherapy TECENTRIQ (Atezolizumab) for Initial Treatment of People With a Specific Type of Metastatic Lung Cancer; 10/04/2018 – NewLink Genetics at Deutsche Bank Health Care Conference May 9; 30/04/2018 – $BMY gives up on its own IDOi from $800M Flexus acquisition Two Ph3 trials just terminated; 07/04/2018 – #2 UPDATED: Keytruda/epacadostat combo crashes in PhIII melanoma study, raising questions about the future of IDO for Incyte $INCY $BMY $NLNK

More notable recent NewLink Genetics Corporation (NASDAQ:NLNK) news were published by: Seekingalpha.com which released: “NewLink Genetics: Explicating The Changing Fundamentals Of A Potential Comeback” on May 17, 2018, also Seekingalpha.com with their article: “Roche backs out of IDO inhibitor development deal with NewLink” published on May 15, 2018, Nasdaq.com published: “Detailed Research: Economic Perspectives on Central European Media Enterprises, Valeant Pharmaceuticals …” on June 05, 2018. More interesting news about NewLink Genetics Corporation (NASDAQ:NLNK) were released by: Streetinsider.com and their article: “NewLink Genetics (NLNK) Highlights Final Results from Two Phase 2 Studies of Indoximod” published on June 04, 2018 as well as Nasdaq.com‘s news article titled: “NewLink Genetics Announces Final Results from Phase 2 Studies of Indoximod in Advanced Melanoma and Metastatic …” with publication date: May 16, 2018.

Analysts await NewLink Genetics Corporation (NASDAQ:NLNK) to report earnings on July, 27. They expect $-0.58 earnings per share, down 1.75% or $0.01 from last year’s $-0.57 per share. After $-0.49 actual earnings per share reported by NewLink Genetics Corporation for the previous quarter, Wall Street now forecasts 18.37% negative EPS growth.

NewLink Genetics Corporation (NASDAQ:NLNK) Institutional Positions Chart